Spiriva All Financial Data in US $ (mln)
Worldwide  
  Overview  

Word Search (Top 10 - by date)
Boehringer Ingelheim Celebrates its 125-year Existence and Looks to the Future With Confidence
Boehringer Ingelheim (August 27, 2010)
Vectura Group plc - Preliminary Results
Vectura (June 07, 2010)
Pearl Therapeutics’ Data for Its Combination Bronchodilator Product, PT003, SUPPORT THE POTENTIAL FOR Improvement in the Treatment of Patients With COPD
Pearl Therapeutics (May 18, 2010)
Pearl Therapeutics’ Bronchodilator Combination Therapeutic for COPD to be Presented at the American Thoracic Society Annual Meeting
Pearl Therapeutics (May 05, 2010)
Pfizer Reports First-Quarter 2010 Results
Pfizer (May 04, 2010)
Boehringer Ingelheim Grows Faster Than the Pharmaceutical Market for the Tenth Time in Succession / Continued High Level of Investment in R&D / Market Launch of Five Innovative Medicines Planned
Boehringer Ingelheim (April 20, 2010)
Sandoz to Acquire Oriel Therapeutics, Gaining Rights to Portfolio of Respiratory Products Targeting Asthma and COPD
Novartis (April 19, 2010)
Pearl Therapeutics Announces Positive Results from Phase 1 Trial of PT003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial
Pearl Therapeutics (March 29, 2010)
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results
Pfizer (February 03, 2010)
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
Pearl Therapeutics (January 06, 2010)

Displaying 10 out of a possible 160 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Summary Product Name Information
Product: Spiriva
Generic Name:   tiotropium bromide
Therapeutic Subcategory:     Anti-cholinergics
Product Sales Summary 2007/08
Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2007 2008 2008
Spiriva2       2,457 3,042   +24%  
Note: Shaded Cells3

More Product Information for EvaluatePharma® subscribers

Subscribers see:
  • Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
  • Details of all events impacting the product
  • Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)

Register to access more FREE content:

  • 2009 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms
Product: Spiriva